DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Morquio Syndrome Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Morquio Syndrome, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Morquio Syndrome Market

• The market size for Morquio Syndrome in the leading markets is expected to grow significantly by 2036.

• The United States accounted for the highest Morquio Syndrome market size among the 7MM in 2025, compared with the EU4 countries, the United Kingdom, and Japan.

• Morquio syndrome is a rare autosomal recessive lysosomal storage disorder affecting approximately 1 in 200,000 live births worldwide and is caused by deficiencies of lysosomal enzymes responsible for glycosaminoglycan degradation.

• According to Puckett et al. (2021), the overall incidence of mucopolysaccharidoses (MPS) in the United States was 0.98 per 100,000 live births, while the birth incidence of MPS IV was reported at 0.14 per 100,000 live births.

• Data from the International Morquio Registry indicate that approximately 68.4% of patients present with the classical phenotype of MPS IVA, while 15.1% exhibit intermediate disease and 9.8% have mild disease.

• According to Utsunomiya et al. (2020), the prevalence of MPS IVA in Japan is approximately 1 in 500,000 individuals.

• According to the National Organization for Rare Disorders (2019), MPS IVA accounts for nearly 95% of Morquio Syndrome cases, whereas MPS IVB represents approximately 5% of affected individuals.

• BioMarin Pharmaceutical’s VIMIZIM (elosulfase alfa) remains the only approved disease-specific enzyme replacement therapy for Morquio Syndrome Type A (MPS IVA), while treatment options for MPS IVB remain limited, highlighting substantial unmet medical needs.

• Although no approved gene therapies are currently available, hematopoietic stem cell transplantation (HSCT) and gene therapy continue to be investigated as promising long-term treatment strategies capable of correcting the underlying enzyme deficiency.

Keen to know more about the market? Request our sample page at: https://www.delveinsight.com/sample-request/morquio-syndrome-market

Key Factors Driving the Morquio Syndrome Market

Increasing Awareness and Early Diagnosis of Rare Genetic Disorders

Growing awareness among healthcare professionals, improvements in genetic testing, and expanding newborn screening programs are enabling earlier diagnosis of Morquio Syndrome. Early identification allows timely initiation of treatment, improving long-term clinical outcomes and supporting market growth.

Expanding Adoption of Enzyme Replacement Therapy

Enzyme replacement therapy remains the cornerstone of treatment for patients with MPS IVA. Weekly administration of VIMIZIM (elosulfase alfa) helps compensate for deficient GALNS enzyme activity, reducing glycosaminoglycan accumulation and improving systemic manifestations, thereby driving continued market expansion.

Growing Interest in Gene-Based and Curative Treatment Approaches

Although still investigational, gene therapy and hematopoietic stem cell transplantation are attracting increasing research interest as potential one-time, long-term therapeutic options capable of addressing the underlying cause of Morquio Syndrome. Continued investment in advanced therapies is expected to create future market opportunities.

Morquio Syndrome Competitive Landscape

The current Morquio Syndrome treatment landscape is dominated by BioMarin Pharmaceutical’s VIMIZIM (elosulfase alfa), the first approved enzyme replacement therapy specifically developed for MPS IVA. VIMIZIM supplements the deficient N-acetylgalactosamine-6-sulfatase (GALNS) enzyme, promoting lysosomal degradation of accumulated glycosaminoglycans and improving systemic disease manifestations. However, despite its clinical benefits, the therapy does not reverse established skeletal abnormalities, leaving significant unmet clinical needs.

Current research efforts are increasingly focused on innovative treatment strategies including hematopoietic stem cell transplantation (HSCT) and gene therapy, both of which have the potential to provide long-term correction of enzyme deficiency. While gene therapy has demonstrated encouraging preclinical results and HSCT has shown favorable long-term outcomes in selected patients, these approaches remain investigational, creating opportunities for future innovation within the Morquio Syndrome market.

Discover more about therapies set to grab major Morquio Syndrome market share @ Morquio Syndrome Treatment Landscape

Recent Developments in the Morquio Syndrome Market

• In 2024, BioMarin Pharmaceutical reported full-year VIMIZIM sales of USD 739.8 million, reflecting the continued adoption of enzyme replacement therapy for patients with Morquio A syndrome.

• For the first nine months of 2025, VIMIZIM generated approximately USD 587 million in sales, demonstrating sustained commercial performance across major markets.

• VIMIZIM’s patent exclusivity in the United States extends through 2032, while European patent protection continues through 2031, supporting the therapy’s market position over the coming years.

• In 2023, BioMarin Pharmaceutical received a subpoena from the US Department of Justice (DOJ) requesting documents related to sponsored testing programs for VIMIZIM and NAGLAZYME. The company stated that it is cooperating fully with the investigation.

• Research efforts continue to evaluate hematopoietic stem cell transplantation (HSCT) and gene therapy as potential long-term treatment strategies capable of correcting the underlying enzyme deficiency associated with Morquio Syndrome, although these approaches remain investigational.

What is Morquio Syndrome?

Morquio Syndrome, also known as Mucopolysaccharidosis IV (MPS IV), is a rare autosomal recessive lysosomal storage disorder caused by deficiencies of enzymes responsible for degrading glycosaminoglycans (GAGs). The resulting accumulation of undegraded substrates leads to progressive multisystem disease affecting the skeletal, respiratory, cardiac, visual, and musculoskeletal systems.

The disorder consists of two genetically distinct subtypes: MPS IVA, caused by mutations in the GALNS gene, and MPS IVB, resulting from mutations in the GLB1 gene. Type A represents the vast majority of diagnosed cases and generally presents with more severe clinical manifestations than Type B.

Diagnosis typically involves laboratory assessment of urinary keratan sulfate, enzyme activity testing in leukocytes, and confirmatory molecular genetic testing. Although no cure currently exists, disease management relies on enzyme replacement therapy, multidisciplinary supportive care, orthopedic interventions, respiratory management, and rehabilitation to improve quality of life.

Morquio Syndrome Epidemiology Segmentation

The Morquio Syndrome epidemiology section provides insights into the historical and current Morquio Syndrome patient pool and forecasted trends across the seven major markets. The Morquio Syndrome market report provides epidemiological analysis for the study period 2022–2036, segmented into:

• Total Diagnosed Prevalent Cases of Morquio Syndrome

• Type-specific Diagnosed Prevalent Cases of Morquio Syndrome

• Total Treated Cases of Morquio Syndrome

Scope of the Morquio Syndrome Market Report

• Therapeutic Assessment: Current marketed therapies and emerging treatment approaches for Morquio Syndrome

• Morquio Syndrome Market Dynamics: Key market forecast assumptions, pricing trends, reimbursement landscape, and market outlook

• Key Companies: BioMarin Pharmaceutical and others

• Key Therapies: VIMIZIM (elosulfase alfa), Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplantation (HSCT), and other supportive therapies

• Competitive Intelligence Analysis: SWOT analysis and market opportunity assessment

• Unmet Needs, KOL Views, Analyst Views, Market Access, and Reimbursement Analysis

To know more about companies working in the Morquio Syndrome treatment market, visit @ Morquio Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

• Morquio Syndrome Market Report Introduction

• Executive Summary for Morquio Syndrome

• SWOT Analysis of Morquio Syndrome

• Morquio Syndrome Patient Share (%) Overview at a Glance

• Morquio Syndrome Market Overview at a Glance

• Morquio Syndrome Background and Overview

• Morquio Syndrome Epidemiology and Patient Population

• Country-Specific Patient Population of Morquio Syndrome

• Morquio Syndrome Current Treatment and Medical Practices

• Morquio Syndrome Unmet Needs

• Morquio Syndrome Marketed Therapies

• Morquio Syndrome Market Outlook

• Country-Wise Morquio Syndrome Market Analysis (2022–2036)

• Morquio Syndrome Market Access and Reimbursement

• Morquio Syndrome Market Drivers

• Morquio Syndrome Market Barriers

• Morquio Syndrome Appendix

• Morquio Syndrome Report Methodology

• DelveInsight Capabilities

• Disclaimer

• About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/